Alterity Therapeutics Ltd Market Cap ($44.97 Million)
Market Cap & Net Worth: Alterity Therapeutics Ltd (ATHE)
Alterity Therapeutics Ltd market cap. Alterity Therapeutics Ltd (NASDAQ:ATHE) has a market capitalization of $44.97 Million ($44.97 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22114 globally and #4928 in its home market, demonstrating a 18.75% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alterity Therapeutics Ltd's stock price $2.47 by its total outstanding shares 18208368 (18.21 Million). Also see ATHE cash generation efficiency for how efficiently the company converts equity into cash flow.
Alterity Therapeutics Ltd Market Cap History (2015–2026)
Alterity Therapeutics Ltd market cap history from 2015 to 2026. Data shows change from $790.97 Million to $44.97 Million (-24.44% CAGR). Check ATHE stock price for real-time trading data and today's change.
Index Memberships
Alterity Therapeutics Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #631 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2093 of 3165 |
Weight: Alterity Therapeutics Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Alterity Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alterity Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Alterity Therapeutics Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
10.31x
Alterity Therapeutics Ltd's market cap is 10.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $568.10 Million | $132.40K | -$7.54 Million | 4290.92x | N/A |
| 2018 | $233.07 Million | $201.17K | -$8.27 Million | 1158.53x | N/A |
| 2019 | $142.03 Million | $108.54K | -$11.96 Million | 1308.53x | N/A |
| 2020 | $243.99 Million | $411.57K | -$10.06 Million | 592.84x | N/A |
| 2021 | $131.10 Million | $4.34 Million | -$15.31 Million | 30.21x | N/A |
| 2022 | $63.40 Million | $5.12 Million | -$12.85 Million | 12.37x | N/A |
| 2023 | $45.34 Million | $3.92 Million | -$13.81 Million | 11.58x | N/A |
| 2024 | $60.27 Million | $4.02 Million | -$19.12 Million | 15.00x | N/A |
| 2025 | $56.08 Million | $5.44 Million | -$12.15 Million | 10.31x | N/A |
Competitor Companies of ATHE by Market Capitalization
Companies near Alterity Therapeutics Ltd in the global market cap rankings as of November 4, 2026. Also see ATHE total asset value for a full breakdown of the balance sheet.
Key companies related to Alterity Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Alterity Therapeutics Ltd (2015–2026)
Market capitalization of Alterity Therapeutics Ltd from 2015 to today. Between 2015 and today, Alterity Therapeutics Ltd's market cap moved from $790.97 Million to $ 44.97 Million, with a yearly change of -24.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $44.97 Million | -19.81% |
| 2025 | $56.08 Million | -6.95% |
| 2024 | $60.27 Million | +32.93% |
| 2023 | $45.34 Million | -28.49% |
| 2022 | $63.40 Million | -51.64% |
| 2021 | $131.10 Million | -46.27% |
| 2020 | $243.99 Million | +71.79% |
| 2019 | $142.03 Million | -39.06% |
| 2018 | $233.07 Million | -58.97% |
| 2017 | $568.10 Million | +91.41% |
| 2016 | $296.80 Million | -62.48% |
| 2015 | $790.97 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Alterity Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $44.97 Million USD |
| MoneyControl | $44.97 Million USD |
| MarketWatch | $44.97 Million USD |
| marketcap.company | $44.97 Million USD |
| Reuters | $44.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more